Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung transplant study tests whether ECMO should be used routinely or only when needed

NCT ID NCT06615492

Disease control Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two ways of using a heart-lung support machine (ECMO) during lung transplants: using it routinely for all patients versus using it only when problems arise. About 218 adults with end-stage lung disease will take part. The goal is to see which approach leads to more days free from intensive care and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Extracorporeal membrane oxygenation (ECMO) device
What this could lead to
If it works, this could show that using ECMO only when needed is safer and just as effective as using it routinely, potentially reducing complications like bleeding and infection.
What could go wrong
This is a single-center trial with 218 participants, so results may not apply to all hospitals. ECMO itself carries risks like bleeding and clotting, and the selective approach might not prevent severe complications in some patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 218 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2024

Expected to finish

Jan 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients undergoing lung transplant surgery Exclusion Criteria: * Inability to provide consent for the study * Retransplantation * Multi-organ transplantation * Contra-indication to standard heparin anticoagulation (e.g., heparin-induced thrombocytopenia) * Lung transplant recipients where intraoperative cardiopulmonary support is mandatory: * Severe pulmonary hypertension (PH): 1. Systolic pulmonary artery pressure (PAP) ≥ 80 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement 2. Mean PAP ≥ 55 mm Hg on the most recent echocardiography, right heart catheterization, or pulmonary artery catheter measurement 3. The ratio of mean pulmonary to systemic artery pressure of \> 0.66 * Moderate to severe right ventricular (RV) hypokinesis or dysfunction * Left ventricular dysfunction: Defined as ejection fraction (LVEF) less than 45% on echocardiography, ventriculography, computed tomography (CT), or magnetic resonance imaging (MRI) * Patients requiring concomitant cardiac surgery: For example, significant coronary artery disease (CAD) requiring surgical grafting

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset interstitial lung disease pulmonary fibrosis respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease) Interstitial lung disease (ILD) Pulmonary fibrosis Respiratory failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Centre Hospitalier de l'Universite de Montreal

    RECRUITING

    Montreal, Quebec, H2X3E4, Canada

  • Univeristy of Alberta & Alberta Health Services

    NOT_YET_RECRUITING

    Edmonton, Alberta, T6G2G3, Canada

  • University Health Network / Toronto General Hospiatl

    NOT_YET_RECRUITING

    Toronto, Ontario, M5G 1M1, Canada

  • Vancouver General Hospital

    NOT_YET_RECRUITING

    Vancouver, British Columbia, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.